Downing Healthcare Ventures portfolio company, TidalSense, has successfully launched its AI technology for assessing chronic obstructive pulmonary disease (COPD).
After four years of development, the N-Tidal technology will be piloted over the next 12 weeks by around 600 patients in Oxford.
COPD is an uncurable chronic lung condition affecting more than 1.2 million people in the UK, and respiratory disease represents the third most common cause of death in England. Patients breathe into the device and a carbon dioxide sensor measures changes in lung function from a single breath recording.
Over the next six to nine months, the technology will start to become a diagnostic device, drastically cutting testing time and improving access and ease-of-use for patients.
Dr Ameera Patel, CEO of TidalSense, said: "We desperately need to arm primary care doctors with accurate, easy-to-perform tests that enable the early and accurate diagnosis of patients, at the point at which they present with symptoms."